Multitude Therapeutics

📍 Redwood City, United States🗓 Founded 2018👥 8 employees💰 Last funded Jan 2021
Biotechnology Research🌐 multitudetherapeutics.info
Website LinkedIn
Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Multitude Therapeutics?
Multitude Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Multitude Therapeutics last raise funding?
The most recent investment in Multitude Therapeutics recorded on gritt.io was in January 2021.
When was Multitude Therapeutics founded?
Multitude Therapeutics was founded in 2018.
What industry is Multitude Therapeutics in?
Multitude Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Multitude Therapeutics based?
Multitude Therapeutics is headquartered in Redwood City, United States.